Syntocinon 40 IE/ml neusspray

DRUG6 trials

Sponsors

Fondazione Santa Lucia IRCCS, UZ Leuven, St. Olavs Hospital HF

Conditions

Autism Spectrum Disorder (ASD)Autism spectrum disorder (ASD)Benzodiazepine dependence (F13.2)Healthy childrensubstance use disorder

Phase 1

Oxytocin and attachment development: Looking beyond the expected?

RecruitingCTIS2024-518004-49-00

UZ LeuvenHealthy children

Start: 2025-10-28Target: 200Updated: 2024-12-17

Phase 2

Leveraging the neural mechanisms of social reward for drug relapse prevention

Not yet recruitingCTIS2023-504518-31-00

Fondazione Santa Lucia IRCCSsubstance use disorder

Target: 70Updated: 2023-07-12

Effects of intranasal oxytocin in the treatment of benzodiazepine withdrawal: A pilot randomized parallel group placebo-controlled trial

Not yet recruitingCTIS2024-516262-11-00

St. Olavs Hospital HFBenzodiazepine dependence (F13.2)

Target: 60Updated: 2025-02-27

Phase 3

Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin administration

WithdrawnCTIS2023-505253-41-00

UZ LeuvenAutism Spectrum Disorder (ASD)

Target: 140Updated: 2023-09-25

Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin administration

RecruitingCTIS2023-505253-41-01

UZ LeuvenAutism Spectrum Disorder (ASD)

Start: 2024-06-18Target: 140Updated: 2025-12-03

Evaluation of oxytocin treatment in children with autism and intellectual disability’, Multiple-dose Oxytocine - ASD and Intellectual Disability

RecruitingCTIS2024-513436-14-00

UZ LeuvenAutism spectrum disorder (ASD)

Start: 2023-05-30Target: 80Updated: 2025-04-04